EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adverse events following HPV vaccine reported to the Vaccine Adverse Event Reporting System

Unerwünschte Ereignisse nach HPV-Impfung, gemeldet an das Vaccine Adverse Event Reporting System

Siqi Zhang iD, Yu Li, Miaomiao Liu, Jiajia Yang, Xiong Wang, Mingshan Wang

PLOS One · 17.06.2026 · 21 (6) · e0351652

DOI: 10.1371/journal.pone.0351652 ↗

Auf einen Blick

In VAERS wurden 77.909 Meldungen zu HPV-Impfungen von 2006 bis 2024 ausgewertet. Am häufigsten wurden Synkopen signalisiert; POTS zeigte das stärkste Signal.

Fragestellung

Welche unerwünschten Ereignisse wurden nach HPV-Impfung im VAERS von 2006 bis 2024 gemeldet?

Methode

Analyse von VAERS-Daten mit vier Disproportionalitätsanalysen (ROR, PRR, BCPNN, MGPS). Signale galten nur bei gleichzeitig positiver Bewertung in allen 4 Methoden.

Ergebnisse

77.909 AE-Meldungen; 68,4 % betrafen Frauen und 48,7 % Personen unter 18 Jahren. Schwere AEs: 11.659 Meldungen. Häufige AEs: Kopfschmerz und Fatigue. Etwa 90 % traten binnen 30 Tagen auf.

Schlussfolgerung der Autor:innen

Die Studie liefert eine aktualisierte pharmakovigilanzielle Bewertung der nach HPV-Impfung gemeldeten unerwünschten Ereignisse und zeigt Muster sowie statistische Signale, die weiter untersucht werden sollten.

Kernaussagen

  • 77.909 HPV-impfbezogene AE-Meldungen in VAERS
  • Synkope häufigstes Signal; POTS stärkstes Signal
  • Etwa 90 % der AEs innerhalb von 30 Tagen nach Impfung

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 17.06.2026. Verfasst von Siqi Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Adverse Drug Reaction Reporting Systems, Papillomavirus Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vaccination against high-risk HPV types is a key preventive measure. However, concerns regarding vaccine safety may hinder vaccination efforts. This study aims to evaluate adverse events (AEs) reported in the Vaccine Adverse Event Reporting System (VAERS) following HPV vaccination from 2006 to 2024, providing insights into its safety profile.

Methods

We analyzed VAERS data, a spontaneous reporting system containing de-identified AE reports. Four disproportionality analyses (ROR, PRR, BCPNN, and MGPS) were applied, and adverse event signals were defined only when the positive criteria were simultaneously met across all four methods. Statistical analyses were performed using R software and Microsoft Excel, with a significance threshold of p < 0.05.

Results

A total of 77,909 HPV vaccine-related AE reports were analyzed, with 68.4% involving females and 48.7% affecting individuals under 18. Serious AEs accounted for 11,659 reports, with headache and fatigue being the most common. Syncope was the most frequent signal, while postural orthostatic tachycardia syndrome (POTS) exhibited the strongest signal strength. Approximately 90% of AEs occurred within 30 days post-vaccination. Among vaccine types, HPV4 had the highest number of reports, and intramuscular injection was the most common administration route.

Conclusion

This study offers an updated pharmacovigilance assessment of adverse events reported following HPV vaccination, highlighting reported patterns and statistical signals that may warrant further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus VaccinesAdverse Drug Reaction Reporting SystemsPapillomavirus InfectionsHumansFemaleMaleAdolescentChildVaccinationHuman Papillomavirus VirusesYoung AdultAdultChild, Preschool

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Department of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
  • Department of Medical Oncology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
  • Eye Institute & Affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China.

ORCID-Profile: Siqi Zhang

Zitieren

APA

Zhang, S., Li, Y., Liu, M., Yang, J., Wang, X., & Wang, M. (2026). Adverse events following HPV vaccine reported to the Vaccine Adverse Event Reporting System. PLOS One, 21(6), e0351652. https://doi.org/10.1371/journal.pone.0351652

Vancouver

Zhang S, Li Y, Liu M, Yang J, Wang X, Wang M. Adverse events following HPV vaccine reported to the Vaccine Adverse Event Reporting System. PLOS One. 2026;21(6):e0351652. doi:10.1371/journal.pone.0351652

BibTeX
@article{Zhang2026,
  author = {Zhang, Siqi and Li, Yu and Liu, Miaomiao and Yang, Jiajia and Wang, Xiong and Wang, Mingshan},
  title = {Adverse events following HPV vaccine reported to the Vaccine Adverse Event Reporting System},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {6},
  pages = {e0351652},
  doi = {10.1371/journal.pone.0351652}
}
Kostenlos starten →